A recent study reveals that 50% of individuals who stop using Wegovy (semaglutide) and Zepbound (tirzepatide) regain the weight they lost within a year. The findings underscore the challenges of long-term weight management and signal potential shifts in patient behavior toward alternative weight-loss strategies.
- 50% of patients regain lost weight after stopping Wegovy or Zepbound within one year
- Average weight loss during treatment: 15% of initial body weight
- 38% of discontinued users adopted alternative weight-loss methods
- Non-prescription weight-loss product sales rose 22% year-over-year
- Fitness tech adoption increased 18% among adults aged 30–55
- GLP-1 market projected to reach $150 billion by 2030
A new analysis of patient outcomes shows that half of individuals who discontinue GLP-1 receptor agonist therapies—specifically Wegovy and Zepbound—experience full or partial weight regain within 12 months. The study tracked over 12,000 patients across clinical and real-world settings, with an average weight loss of 15% during treatment. After cessation, 50% of participants returned to or exceeded their pre-treatment weight, indicating a high rate of metabolic rebound. The data highlight a critical limitation in current weight-loss pharmacotherapy: while Wegovy and Zepbound deliver significant short-term results, sustained weight maintenance requires ongoing treatment. Patients who stopped therapy reported increased appetite, reduced energy, and diminished motivation, factors that contributed to the weight rebound. Among those who discontinued use, nearly 38% attempted alternative weight-loss methods, including dietary changes, exercise regimens, and non-prescription supplements. The findings carry implications for healthcare providers, insurers, and pharmaceutical manufacturers. With the global GLP-1 market projected to reach $150 billion by 2030, the high discontinuation rate raises concerns about patient adherence and long-term care models. Manufacturers may need to develop strategies to support patients beyond the initial treatment phase, including maintenance programs and behavioral support. Market indicators suggest growing interest in alternative weight-loss interventions. Non-prescription weight-loss products have seen a 22% increase in sales in the past year, while fitness technology adoption among adults aged 30–55 rose by 18%. These trends reflect a broader shift in patient behavior, driven by cost, access, and concerns about dependency on injectable therapies.